| Oxime radical promoted dioxygenation, oxyamination, and diamination of alkenes: synthesis of isoxazolines and cyclic nitrones B Han, XL Yang, R Fang, W Yu, C Wang, XY Duan, S Liu Angewandte Chemie International Edition 35 (51), 8816-8820, 2012 | 206 | 2012 |
| Biased multicomponent reactions to develop novel bromodomain inhibitors MR McKeown, DL Shaw, H Fu, S Liu, X Xu, JJ Marineau, Y Huang, ... Journal of medicinal chemistry 57 (21), 9019-9027, 2014 | 125 | 2014 |
| HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib G Yang, SJ Buhrlage, L Tan, X Liu, J Chen, L Xu, N Tsakmaklis, JG Chen, ... Blood, The Journal of the American Society of Hematology 127 (25), 3237-3252, 2016 | 105 | 2016 |
| Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function B Gui, F Gui, T Takai, C Feng, X Bai, L Fazli, X Dong, S Liu, X Zhang, ... Proceedings of the National Academy of Sciences 116 (29), 14573-14582, 2019 | 83 | 2019 |
| Dual screening of BPTF and Brd4 using protein-observed fluorine NMR uncovers new bromodomain probe molecules AK Urick, LML Hawk, MK Cassel, NK Mishra, S Liu, N Adhikari, W Zhang, ... ACS chemical biology 10 (10), 2246-2256, 2015 | 83 | 2015 |
| A pot-economical and diastereoselective synthesis involving catalyst-free click reaction for fused-triazolobenzodiazepines X Zhang, S Zhi, W Wang, S Liu, JP Jasinski, W Zhang Green chemistry 18 (9), 2642-2646, 2016 | 58 | 2016 |
| Structure-guided design and development of potent and selective dual bromodomain 4 (BRD4)/polo-like kinase 1 (PLK1) inhibitors S Liu, HO Yosief, L Dai, H Huang, G Dhawan, X Zhang, AM Muthengi, ... Journal of medicinal chemistry 61 (17), 7785-7795, 2018 | 55 | 2018 |
| A novel bromodomain inhibitor reverses HIV-1 latency through specific binding with BRD4 to promote Tat and P-TEFb association H Huang, S Liu, M Jean, S Simpson, H Huang, M Merkley, T Hayashi, ... Frontiers in microbiology 8, 1035, 2017 | 53 | 2017 |
| One-pot and catalyst-free synthesis of pyrroloquinolinediones and quinolinedicarboxylates X Zhang, G Dhawan, A Muthengi, S Liu, W Wang, M Legris, W Zhang Green chemistry 19 (16), 3851-3855, 2017 | 37 | 2017 |
| Inhibitors of transcription factors and uses thereof JJ Marineau, JE Bradner, W Zhang, J Qi, MR McKeown, HH Fu, S Liu US Patent 9,975,896, 2018 | 31 | 2018 |
| Small-molecule dual PLK1 and BRD4 inhibitors are active against preclinical models of pediatric solid tumors N Timme, Y Han, S Liu, HO Yosief, HD García, Y Bei, F Klironomos, ... Translational oncology 13 (2), 221-232, 2020 | 26 | 2020 |
| Stereoselective synthesis of fused tetrahydroquinazolines through one-pot double [3+ 2] dipolar cycloadditions followed by [5+ 1] annulation X Zhang, K Pham, S Liu, M Legris, A Muthengi, JP Jasinski, W Zhang Beilstein journal of organic chemistry 12 (1), 2204-2210, 2016 | 24 | 2016 |
| Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4+ T cells ex vivo D Zhou, T Hayashi, M Jean, W Kong, G Fiches, A Biswas, S Liu, ... Science Advances 6 (29), eaba1941, 2020 | 21 | 2020 |
| Assessment of bromodomain target engagement by a series of BI2536 analogues with miniaturized BET‐BRET LW Koblan, DL Buckley, CJ Ott, ME Fitzgerald, SWJ Ember, JY Zhu, S Liu, ... ChemMedChem 11 (23), 2575-2581, 2016 | 20 | 2016 |
| Fluorescent visualization of Src by using dasatinib‐BODIPY ML Vetter, Z Zhang, S Liu, J Wang, HY Cho, J Zhang, W Zhang, NS Gray, ... ChemBioChem 15 (9), 1317-1324, 2014 | 19 | 2014 |
| Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors A Muthengi, VK Wimalasena, HO Yosief, MJ Bikowitz, LH Sigua, T Wang, ... Journal of medicinal chemistry 64 (9), 5787-5801, 2021 | 18 | 2021 |
| Diversified application of barcoded PLATO (PLATO-BC) platform for identification of protein interactions W Kong, T Hayashi, G Fiches, Q Xu, MZ Li, J Que, S Liu, W Zhang, J Qi, ... Genomics, Proteomics and Bioinformatics 17 (3), 319-331, 2019 | 8 | 2019 |
| Dual PLK1 and BRD4 inhibition has synergistic therapeutic effects against high-risk rhabdomyosarcoma N Timme, S Liu, H Yosief, HD García, I MacArthur, A Szymansky, C Dohna, ... Cancer Research 78 (13_Supplement), 2624-2624, 2018 | 1 | 2018 |
| Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions M Li, W Kong, T Hayashi, G Fiches, Q Xu, MZ Li, J Que, S Liu, W Zhang, ... | | 2019 |
| Development of Small Molecules as New Bromodomain Inhibitors for Cancer and Other Diseases S Liu | | 2018 |
James BradnerNovartis Institutes for BioMedical ResearchVerified email at novartis.com
